EP4031121A4 - Formes posologiques et procédés pour la formation de bupropion énantiomériquement enrichi ou pur - Google Patents

Formes posologiques et procédés pour la formation de bupropion énantiomériquement enrichi ou pur Download PDF

Info

Publication number
EP4031121A4
EP4031121A4 EP20866164.5A EP20866164A EP4031121A4 EP 4031121 A4 EP4031121 A4 EP 4031121A4 EP 20866164 A EP20866164 A EP 20866164A EP 4031121 A4 EP4031121 A4 EP 4031121A4
Authority
EP
European Patent Office
Prior art keywords
methods
dosage forms
enantiomerically enriched
pure bupropion
bupropion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20866164.5A
Other languages
German (de)
English (en)
Other versions
EP4031121A1 (fr
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74884634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4031121(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2019/052210 external-priority patent/WO2020061486A2/fr
Priority claimed from US16/830,637 external-priority patent/US20200222339A1/en
Priority claimed from US16/907,691 external-priority patent/US11433035B2/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP4031121A1 publication Critical patent/EP4031121A1/fr
Publication of EP4031121A4 publication Critical patent/EP4031121A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP20866164.5A 2019-09-20 2020-08-18 Formes posologiques et procédés pour la formation de bupropion énantiomériquement enrichi ou pur Pending EP4031121A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2019/052210 WO2020061486A2 (fr) 2018-09-20 2019-09-20 Formes posologiques et procédés d'obtention de bupropion énantiomériquement enrichi ou pur
US202062971174P 2020-02-06 2020-02-06
US202062978626P 2020-02-19 2020-02-19
US202062992060P 2020-03-19 2020-03-19
US16/830,637 US20200222339A1 (en) 2018-09-20 2020-03-26 Dosage forms and methods for enantiomerically enriched or pure bupropion
US16/907,691 US11433035B2 (en) 2018-09-20 2020-06-22 Dosage forms and methods for enantiomerically enriched or pure bupropion
PCT/US2020/046755 WO2021055124A1 (fr) 2019-09-20 2020-08-18 Formes posologiques et procédés pour la formation de bupropion énantiomériquement enrichi ou pur

Publications (2)

Publication Number Publication Date
EP4031121A1 EP4031121A1 (fr) 2022-07-27
EP4031121A4 true EP4031121A4 (fr) 2022-11-30

Family

ID=74884634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20866164.5A Pending EP4031121A4 (fr) 2019-09-20 2020-08-18 Formes posologiques et procédés pour la formation de bupropion énantiomériquement enrichi ou pur

Country Status (15)

Country Link
EP (1) EP4031121A4 (fr)
JP (2) JP2022549192A (fr)
KR (1) KR20220066930A (fr)
CN (1) CN114423417A (fr)
AU (3) AU2020349419B2 (fr)
BR (1) BR112022005045A2 (fr)
CA (2) CA3287347A1 (fr)
CO (1) CO2022003126A2 (fr)
CR (1) CR20220119A (fr)
EC (1) ECSP22030119A (fr)
IL (1) IL291514A (fr)
MX (1) MX2022003346A (fr)
NZ (1) NZ786429A2 (fr)
PE (1) PE20221314A1 (fr)
WO (1) WO2021055124A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022003346A (es) * 2019-09-20 2022-04-11 Axsome Therapeutics Inc Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013014166A (es) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Enantiomeros activos y sus sales para el tratamiento de la obesidad.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
WO2019165379A1 (fr) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (fr) * 1998-01-29 1999-08-05 Sepracor Inc. Utilisations pharmaceutiques de (+)-bupropion optiquement pur
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US20190216800A1 (en) * 2013-11-05 2019-07-18 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2022003346A (es) * 2019-09-20 2022-04-11 Axsome Therapeutics Inc Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013014166A (es) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Enantiomeros activos y sus sales para el tratamiento de la obesidad.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
WO2019165379A1 (fr) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KHARASCH EVAN D. ET AL: "Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 48, no. 4, 1 April 2008 (2008-04-01), US, pages 464 - 474, XP093235496, ISSN: 0091-2700, DOI: 10.1177/0091270008314254 *
MUSSO ET AL: "Synthesis and evaluation of the antidepressant activity of the enentiomers of bupropion", CHIRALITY, WILEY-LISS, NEW YORK, US, vol. 5, no. 7, 1 January 1993 (1993-01-01), pages 495 - 500, XP002107656, ISSN: 0899-0042, DOI: 10.1002/CHIR.530050704 *
See also references of WO2021055124A1 *

Also Published As

Publication number Publication date
KR20220066930A (ko) 2022-05-24
ECSP22030119A (es) 2022-05-31
NZ786429A (en) 2025-08-29
PE20221314A1 (es) 2022-09-07
JP2022549192A (ja) 2022-11-24
AU2020349419B2 (en) 2023-11-02
AU2020349419A1 (en) 2022-03-24
NZ786429A2 (en) 2026-01-30
CO2022003126A2 (es) 2022-04-19
MX2022003346A (es) 2022-04-11
IL291514A (en) 2022-05-01
BR112022005045A2 (pt) 2022-07-05
CR20220119A (es) 2022-06-22
AU2026201399A1 (en) 2026-03-19
CA3154718C (fr) 2026-02-24
JP2024059812A (ja) 2024-05-01
WO2021055124A1 (fr) 2021-03-25
CA3287347A1 (en) 2025-11-29
CA3154718A1 (fr) 2021-03-25
CN114423417A (zh) 2022-04-29
EP4031121A1 (fr) 2022-07-27
AU2024200081A1 (en) 2024-01-25
AU2024200081B2 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
IL276871A (en) Pure bupropion dosage forms and methods for enantiomeric distortion purposes
EP3875458A4 (fr) Composé de type diphényle, son intermédiaire, son procédé de préparation, sa composition pharmaceutique et ses applications
EP3868367A4 (fr) Comprimé buccal micro-effervescent et son procédé de préparation
EP3983062A4 (fr) Systèmes et procédés de traitement esthétique
IL287905A (en) A pharmaceutical preparation containing brexanolone, gnaxolone or zoranolone and its use
WO2020061486A3 (fr) Formes posologiques et procédés d'obtention de bupropion énantiomériquement enrichi ou pur
EP3992194A4 (fr) Composé de benzodiazépine, son procédé de préparation et son utilisation en médecine
EP3805212A4 (fr) Composé 3-oxazolinone, procédé de préparation correspondant, et utilisation pharmaceutique associée
EP3773541A4 (fr) Composition isotopiquement modifiée et ses utilisations thérapeutiques
EP4082579A4 (fr) Polynucléotide et composition médicinale
EP3813842A4 (fr) Composition pharmaceutique et son procédé de préparation
EP3765081A4 (fr) Composition photosensible antimicrobienne et procédé
CA3287347A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK1257997A1 (zh) β受体阻滞剂的S-对映体富集组合物用於治疗肌肉无力
EP4017589A4 (fr) Méthodes thérapeutiques et utilisations associées
WO2010048384A3 (fr) Compositions d'arformotérol et de tiotropium et leurs procédés d'utilisation
IL284980B1 (en) Heteroaryl-azacyclic-oxo-amide compound, pharmaceutical preparation and pharmaceutical preparation for use in the treatment
HK40068404A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
GB201908229D0 (en) Microneedles and methods for the manufacture thereof
HK40041795A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
EP4054558A4 (fr) Méthodes et compositions pour la thérapie du diabète sucré de type 2
EP4001262C0 (fr) Composé contenant du phényle, intermédiaire correspondant, procédé de préparation correspondant, et application correspondante
SG10202000012QA (en) Composition for promoting glucolipid metabolism, and preparation and application thereof
SG11202107799XA (en) Enriched water formulations and processes for preparation thereof
HK40049543A (en) Composition and method for inhalation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068404

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031135000

Ipc: A61K0031137000

A4 Supplementary search report drawn up and despatched

Effective date: 20221028

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20221024BHEP

Ipc: A61P 25/24 20060101ALI20221024BHEP

Ipc: A61K 31/137 20060101AFI20221024BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250102